Skip to content
zameds

Amlodipine, atorvastatin (Caduet)

Amlodipine, atorvastatin

Viatris Healthcare (Pty) Ltd

Registration

Applicant
Viatris Healthcare (Pty) Ltd
Registrations
6

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Caduet 5 mg/10 MG

EACH TABLET CONTAINS AMLODIPINE BESYLATE EQUIVALENT TO AMLODIPINE 5,0 mg ATORVASTATIN 10,0 mg

5 mg/10 mgA390326A39/7.0/0326RegisteredNot determinedNone
Caduet 5 mg/20 MG

EACH TABLET CONTAINS AMLODIPINE BESYLATE EQUIVALENT TO AMLODIPINE 5,0 mg ATORVASTATIN 20,0 mg

5 mg/20 mgA390327A39/7.0/0327RegisteredNot determinedNone
Caduet 10 mg/10 MG

EACH TABLET CONTAINS AMLODIPINE BESYLATE EQUIVALENT TO AMLODIPINE 10,0 mg ATORVASTATIN 10,0 mg

10 mg/10 mgA390330A39/7.0/0330RegisteredNot determinedNone
Caduet 10 mg/20 MG

EACH TABLET CONTAINS AMLODIPINE BESYLATE EQUIVALENT TO AMLODIPINE 10,0 mg ATORVASTATIN 20,0 mg

10 mg/20 mgA390331A39/7.0/0331RegisteredNot determinedNone
Caduet 10 mg/40 MG

EACH TABLET CONTAINS AMLODIPINE BESYLATE EQUIVALENT TO AMLODIPINE 10,0 mg ATORVASTATIN 40,0 mg

10 mg/40 mgA390332A39/7.0/0332RegisteredNot determinedNone
Caduet 10 mg/80 MG

EACH TABLET CONTAINS AMLODIPINE BESYLATE EQUIVALENT TO AMLODIPINE 10,0 mg ATORVASTATIN 80,0 mg

10 mg/80 mgA390333A39/7.0/0333RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Atorvastatin

    Consolidated Schedules 06 July 2026, line 5376

  • S3: Amlodipine

    Consolidated Schedules 06 July 2026, line 3138

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles